The EU Pharma Package[11] includes the pharmaceutical legislation along with orphan drugs and paediatric medicines legislation and a Council Recommendation to step up the fight against antimicrobial resistance (AMR).
The EU Pharma Package should strike a balance between incentivizing innovation and ensuring timely access to affordable medicines. Streamlined regulatory processes, enhanced collaboration, and transparency are key to improving outcomes. Targeted support for unmet medical needs, adaptive pricing and reimbursement models, and strong intellectual property protection are crucial. Long-term planning and evaluation mechanisms are necessary to adapt to evolving scientific advancements and healthcare needs.
The EU Pharma Package should emphasize the importance of robust intellectual property protection, as it plays a crucial role in incentivizing investments in R&D. Adequate protection will foster a favourable environment for innovation and enable pharmaceutical companies to recoup their investments and continue driving medical advancements.
We, along with the European Federation of Pharmaceutical Industries and Associations, are committed to working with Members of the European Parliament, Council, and other stakeholders to ensure the revised pharmaceutical legislation and patent package meets the needs of patients, our healthcare systems, Member States and Europe’s life science sector.